Souhaitez-vous accéder aux communiqués récents ?

Clinical data on Chemomab's nebokitug for the treatment of PSC will be presented at the scientific conferences DDW25; EASL 2025 and BSG LIVE'25

David Weiner, MD, is rejoining Chemomab as Interim Chief Medical Officer and Clinical Development SVP Jack Lawler has been named Chief Development Officer.

Reported positive 48-week nebokitug data from Phase 2 PSC trial. Reduced risk for disease progression and showed improvement in key markers of fibrosis.

Many preclinical and patient sample studies and positive Phase 2 PSC data suggest nebokitug is potentially a promising new treatment for systemic sclerosis

In 2024 reported positive nebokitug Phase 2 primary sclerosing cholangitis data and aligned on a clear, efficient path to potential FDA regulatory approval

After End-of-Phase 2 meeting, Chemomab and FDA aligned on a clear pathway to regulatory approval—a single pivotal Phase 3 study for the treatment of PSC.

Chemomab will present at the Oppenheimer Heathcare Life Sciences Conference on Feb 11 at 8 am ET and participate in 1x1 investor meetings.

Chemomab management is participating in the Oppenheimer Movers in Rare Disease Summit on Dec 13, 2024 at the Westin Grand Central in NYC.

Oral presentation at AASLD highlights broad clinical activity of Chemomab’s CM-101 across multiple biomarkers and its disease-modifying potential in PSC

In 3Q reported positive CM-101 PSC Ph 2 results. On track for 2 milestones in Q125--FDA agreement on PSC Ph 3 design and Ph 2 open label extension readout.